货号:A109438
同义名:
氟伐他汀钠 水合物
/ Fluvastatin sodium;XU 62-320
Fluvastatin Sodium Salt是一种合成的 HMG-CoA 还原酶抑制剂,IC50 为 8 nM,常用于调节血脂和抗氧化相关研究。
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor. the statin (0.6 and 6 mg/kg/day) inhibited hemoglobin (Hb) content (51%) and vascular endothelial growth factor (VEGF) levels (71%) in the treated group compared with the control group. The inflammatory component, as assessed by N-acetyl-β-D-glucosaminidase activity and tumor necrosis factor-α (TNF-α) level was also decreased by the compound. In the treated group; the inhibition of the enzyme activity was 33% and the cytokine was 67% relative to the control.[4].Untreated Apolipoprotein E–deficient Control mice developed severe hypercholesterolemia and hypertriglyceridemia and had a significantly lower HDL cholesterol level (-70%) compared with the age-matched wild type mice.Compared with ApoE-/- mice, chronic fluvastatin treatment significantly decreased plasma total cholesterol (-53%) and HDL cholesterol levels (-61%) and normalized triglycerides[5]. Fluvastatin is extensively absorbed from the gastrointestinal tract. After absorption, it is nearly completely extracted and metabolised in the liver to 2 hydroxylated metabolites and an N-desisopropyl metabolite, which are excreted in the bile. Approximately 95% of a dose is recovered in the faeces, with 60% of a dose recovered as the 3 metabolites. The 6-hydroxy and N-desisopropyl fluvastatin metabolites are exclusively generated by cytochrome P450 (CYP) 2C9 and do not accumulate in the blood. CYP2C9, CYP3A4, CYP2C8 and CYP2D6 form the 5-hydroxy fluvastatin metabolite[6]. |
作用机制 | Fluvastatin exerts cytoprotective effects against oxidative stress, inducing antioxidant genes through Nrf2/ARE in hCASMCs[3]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00256750 | Kidney Transplantation ... 展开 >> Chronic Kidney Failure 收起 << | Phase 3 | Completed | - | - |
NCT01563731 | Stroke Transi... 展开 >>ent Ischemic Attack Hypertension 收起 << | Phase 4 | Recruiting | November 2018 | Russian Federation ... 展开 >> Almazov Federal Heart, Blood and Endocrinology Centre Recruiting Saint-Petersburg, Russian Federation, 197341 收起 << |
NCT01047501 | Hypertriglyceridemia | Phase 3 | Completed | - | - |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.31mL 0.46mL 0.23mL |
11.54mL 2.31mL 1.15mL |
23.07mL 4.61mL 2.31mL |
CAS号 | 93957-55-2 |
分子式 | C24H25FNNaO4 |
分子量 | 433.448 |
别名 | 氟伐他汀钠 水合物 ;Fluvastatin sodium;XU 62-320 |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere,2-8°C |
溶解方案 |
DMSO: 50 mg/mL(115.35 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 50 mg/mL(115.35 mM),配合低频超声助溶 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
动物实验配方 |
PO 0.5% CMC-Na 40 mg/mL suspension |